News
Important Only
Hyundai Motor to unveil multi-billion-dollar investment in South Korea, source says
By Hyunjoo Jin SEOUL, Feb 25 (Reuters) - Hyundai Motor Group plans to unveil a multi-billion-dollar investment in South Korea's west coast, a source with direct knowledge of the matter said on Wednesday, as the auto group expands into artificial intelligence for autonomous driving and robotic...Reuters
11 minutes ago
METALS-Copper extends gains on restocking bets after China holiday
Feb 25 (Reuters) - Copper extended gains on Wednesday as traders bet on restocking demand after Chinese market participants returned after holidays.The most-traded copper contract SCFcv1 on the Shanghai Futures Exchange climbed 0.82% to 102,440 yuan ($14,907.52) a metric ton as of 0310 GMT.The Shang...Reuters
13 minutes ago
CF PharmTech (HKEX: 2652.HK) Announces NMPA Acceptance of IND Application for ICF004, a Potential First-in-Class Inhaled Dry Powder Candidate Targeting Unmet Needs in PF-ILD
Suzhou, China, February 24, 2026 — CF PharmTech, Inc. (HKEX: 2652.HK) (“CF PharmTech” or the “Company”) today announced that the Investigational New Drug (“IND”) application for ICF004, the Company’s internally developed first-in-class (FIC) inhaled dry powder candidate for the treatment of pulmonary fibrosis (a Class 1 chemical drug candidate), has been accepted by the National Medical Products Administration of China (“NMPA”).The acceptance of the ICF004 IND application marks a key step forward in the Company’s innovative drug research and development efforts and an important milestone in advancing translational innovation based on the Company’s complex respiratory formulation and precision delivery platform. The Company believes progress in the ICF004 program not only supports the clinical development value of a standalone pipeline asset, but also demonstrates its ability to translate high-barrier delivery and formulation platform capabilities into innovative drug clinical development assets.Addressing Unmet Needs in PF-ILD: Resolving Efficacy-Tolerability DilemmaICF004 is intended for the treatment of Progressive Fibrosing Interstitial Lung Disease (“PF-ILD”), a disease area that includes life-threatening indications such as Idiopathic Pulmonary Fibrosis (“IPF”) and Progressive Pulmonary Fibrosis (“PPF”).PF-ILD is characterized by progressively worsening respiratory symptoms and irreversible decline in lung function, and is generally associated with poor prognosis. Using IPF as a representative condition, publicly available data indicate a median survival of approximately 2.8 years and a 5-year survival rate below 40%, underscoring the substantial clinical burden of disease.Oral therapies have been approved globally for the treatment of IPF. Public clinical data and real-world evidence suggest that, while existing therapies may slow decline in lung function to some extent, some patients still face limited survival benefit, significant adverse-event burden, and treatment interruption or discontinuation. For patients coping with both disease progression and treatment-related side effects, there remains an urgent global need for next-generation therapies that can better balance safety, efficacy, and long-term treatment adherence.The Company believes the development rationale for ICF004 is grounded in these unmet needs. The program seeks to explore new delivery and therapeutic pathways on top of existing treatment approaches, with the goal of improving the therapeutic window and patient outcomes.Improving Therapeutic Window Through the Integration of Mechanism Exploration and Formulation Innovation Through Local Targeted DeliveryBased on the Company’s current development strategy, ICF004 uses an inhaled dry powder delivery route designed to deliver the drug directly to lung lesion areas, thereby increasing local pulmonary exposure while minimizing systemic exposure to the extent possible, in pursuit of a better balance between efficacy and safety.The Company positions ICF004 as a candidate integrating mechanism exploration and formulation innovation, and continues to conduct mechanistic research and translational validation around fibrosis-related pathological processes, including inflammation, oxidative stress, and fibroblast activation.Preclinical Findings Demonstrate Differentiated Pulmonary Exposure Profile Supporting Development StrategyAccording to the Company’s completed preclinical studies, ICF004 demonstrated differentiated distribution characteristics between lung tissue exposure and systemic blood exposure following inhaled administration. In relevant studies, the Company observed a significant exposure differential between lung and blood, supporting the project’s subsequent development strategy centered on improving target-organ exposure efficiency and reducing systemic exposure burden through local targeted delivery.In addition, the Company observed anti-fibrotic activity trends for ICF004 in relevant preclinical models. These findings provide supportive information for subsequent clinical development; however, whether they will translate into clinical efficacy and safety advantages in humans remains to be verified in future clinical trials.Platform Validation: Extending from Complex Formulation to Innovative Drug Translational Capability and Strategic SignificanceThe acceptance of the ICF004 IND application marks the first time one of the Company’s innovative drug programs has entered the regulatory acceptance stage. The Company believes the strategic significance of this progress is reflected primarily in the following areas:Validation of platform translational capability — demonstrating the Company’s ability to integrate complex formulations, delivery systems, device engineering, and unmet clinical needs in advancing innovative drug development programs; Strengthening the replicability of R&D pathways — providing methodological and organizational experience for subsequent innovative programs in respiratory and related therapeutic areas; and Enhancing capital market understanding of the Company’s platform-based capabilities — helping investors better understand, beyond the complex formulation business alone, the Company’s medium- to long-term capabilities and potential value drivers in combining delivery technologies, device engineering, and innovative drug clinical translation.Leveraging its capabilities in inhalation delivery, device engineering, regulatory registration, and industrialization, CF PharmTech continues to advance a multi-layered product portfolio and explore opportunities in delivery-enabled innovative drug development across broader disease areas.Next StepsThe Company will continue to advance subsequent clinical development activities for ICF004 in accordance with NMPA requirements, including clinical start-up preparation, subject enrollment arrangements, and phased data readouts.At the same time, the Company will prudently evaluate strategic pathways such as independent development and collaborative development based on the project’s clinical progress, resource allocation, and external partnership opportunities, and will fulfill information disclosure obligations in a timely manner in accordance with applicable regulatory requirements.Important Risks and DisclaimersInnovative drug R&D involves high investment, long development timelines, and significant risks. Uncertainties remain in the subsequent clinical development, regulatory review and approval, and commercialization process of ICF004. The Company reminds investors to exercise rational judgment and be mindful of the risks associated with investing.About CF PharmTechCF PharmTech focuses on the development of complex formulations, small nucleic acid and liposomal drugs, and precision delivery technologies in key therapeutic areas such as respiratory diseases, and has capabilities in inhalation delivery, device engineering, regulatory registration, and industrialization. The Company is advancing a multi-layered product portfolio based on these platform capabilities and continues to explore clinical translation opportunities in innovative drug development.Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements, including but not limited to statements relating to the development, clinical progress, regulatory review, and potential commercialization of ICF004, and the Company’s strategic plans and expectations. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied. Such risks and uncertainties include, but are not limited to, risks related to clinical development, regulatory approval, commercialization, market conditions, and other factors. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, except as required by applicable law or regulation.25/02/2026 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
38 minutes ago
HK Mainland Real Estate Shares Rally. CH OVS G Oceans And Country Gardenup 8%; LVGEM China, China Res Land, Longfor, Agile, Greentown And Cifi Up 5%
HK Mainland Real Estate Shares Rally. CH OVS G Oceans and Country Gardenup 8%; LVGEM China, China Res Land, Longfor, Agile, Greentown and Cifi up 5%.Tiger News
an hour ago
GLOBAL MARKETS-Asia markets rise on better AI sentiment, Trump speech awaited
By Scott Murdoch SYDNEY, Feb 25 (Reuters) - Asia's financial markets were higher on Wednesday with Korean chipmakers leading gains, as investors double down on what they see as the safest bet on artificial intelligence (AI), while the yen remained in focus.Investors rocked by volatility in re...Reuters
2 hours ago
ETF Daily | CIFG Soars 26%; WULX Surges 23%; SOXL Gains 4%; DAMD Sinks 17%; Semis Lead Risk-On Rotation
Market OverviewU.S. stocks advanced on Tuesday, with the S&P 500 adding 0.77% and the Nasdaq Composite firming 1.04%, while the Dow Jones Industrial Average increased 0.76%, keeping major indices near record territory.Across ETFs, flows tilted decisively toward growth and cyclicals; equity index and...Tiger News
2 hours ago
Warner Bros reopens door to Paramount, putting Netflix deal in doubt
Paramount's new bid is for $31 per shareNetflix will have a chance to match Paramount's offerActivist investor Ancora Holdings has pressured Warner Bros, criticized Netflix dealBy Dawn Chmielewski Feb 24 (Reuters) - Warner Bros Discovery WBD.O opened the door on Tuesday to Paramount Skyda...Reuters
2 hours ago
24H | Axon Enterprise Surges 16%; CAVA Group Jumps 9%; Lucid Falls 4%; HP Drops 5%; First Solar Sinks 12%
Taser-maker Axon Enterprise beat Wall Street estimates for fourth-quarter profit, driven by strong demand for its security devices and software products. Shares of the Arizona-based company were up 15.7% in overnight trading.CAVA Group forecast annual same-store sales above Wall Street estimates, be...Tiger News
2 hours ago
24H｜Crypto Stocks Jump As Bitcoin Rises Above $66,000; Upexi up 8%; Canaan up 5%; BMNR up 4%; Circle, Strategy, Coinbase up 3%
Crypto stocks jumped in overnight trading as Bitcoin rose above $66,000 and Ethereum rose to $1,913.Upexi up 8%; Canaan up 5%; BMNR up 4%; Circle, Strategy, Coinbase up 3%; SBET, Robinhood up 2%.Tiger News
2 hours ago
Axon Enterprise Jumps 16% on Q4 Results, Upbeat Guidance
Axon Enterprise, Inc. shares rose 16% in overnight trading after the maker of tasers and body cameras reported quarterly results that topped Wall Street expectations and issued a 2026 outlook calling for 27% to 30% revenue growth.Fourth-quarter revenue was $797 million, up 39% from a year earlier a...Tiger News
3 hours ago
Newmark Appoints Shanting Wong as Head of Research in Singapore
SINGAPORE, Feb. 25, 2026 /PRNewswire/ -- Newmark Group, Inc. (Nasdaq: NMRK) ("Newmark" or "the Company"), a leading commercial real estate advisor and service provider to large institutional investors, global corporations, and other owners and occupiers, announces the appoin...PR Newswire
3 hours ago
MercadoLibre misses quarterly profit estimates but revenue exceeds expectations
Profit decline due to credit and logistics investments, says VPRevenue boosted by Brazil and Mexico, up 45% year-on-yearShares down over 6% after positive initial reaction SAO PAULO, Feb 24 (Reuters) - MercadoLibre MELI.O on Tuesday posted a 12.5% decline in quarterly profit, missing analysts'...Reuters
3 hours ago
HP reckons memory chip crunch will linger next year, warns of PC sales slump
HP does not expect immediate impact from new tariffsExpects double-digit decline in PC unit shipments in 2026Company upbeat on AI-powered PCsBy Jaspreet Singh Feb 24 (Reuters) - HP Inc HPQ.N said on Tuesday it expected volatility in memory chips to persist even into next year and forecast a slump...Reuters
3 hours ago
Japan's Nikkei share average sets record high as AI disruption fear eased
TOKYO, Feb 25 (Reuters) - Japan's Nikkei share price average set a record high on Wednesday as investor apprehension over artificial intelligence disruption eased while the yen weakened.The benchmark Nikkei 225 index .N225 rose 1.1% to 57,956.92 in early trade after touching an intraday peak of ...Reuters
3 hours ago
RPT-ROI-Squaring 'Sell America' with record foreign inflows: McGeever
By Jamie McGeever ORLANDO, Florida, Feb 24 (Reuters) - With the fog of uncertainty around U.S. President Donald Trump's tariffs suddenly thickening again, foreign investors' appetite for U.S. assets is under renewed scrutiny. Yet capital from overseas keeps flowing into U.S. markets at a ...Reuters
3 hours ago
Post-Bell | Nasdaq Rises 1%; Software Stocks Rise with Figma up 11%; AMD Soars 9%; TSMC Jumps 4%; Tesla, Apple up 2%; SanDisk Drops 4%
01 Stock MarketWall Street closed higher on Tuesday, with tech stocks leading the charge as renewed enthusiasm for artificial intelligence offset concerns over potential disruptions caused by the nascent technology.Speculation regarding AI's possible impact on a wide variety of sectors has prompted ...Tiger News
4 hours ago
Lucid sees slower 2026 production growth as fear of supply-chain snags lingers
Lucid expects to produce 25,000-27,000 vehicles in 2026 vs 17,840 in 2025Production of midsize platform to start in Saudi Arabia — CEOSupply-chain disruption led to bigger-than-expected Q4 loss2026 capex projected between $1.2 bln and $1.4 bln By Abhirup Roy and Jaspreet Singh Feb 24 (Reuters) - ...Reuters
4 hours ago
Art Technology Acquisition Announces The Separate Trading Of Its Class A Ordinary Shares And Warrants
Feb 24 (Reuters) - Art Technology Acquisition Corp ARTCU.O:ART TECHNOLOGY ACQUISITION CORP. ANNOUNCES THE SEPARATE TRADING OF ITS CLASS A ORDINARY SHARES AND WARRANTS, COMMENCING FEBRUARY 27, 2026ART TECHNOLOGY ACQUISITION CORP: CLASS A ORDINARY SHARES & WARRANTS WILL TRADE ON NASDAQ GLOBAL MARK...Reuters
5 hours ago
